Extended Data Fig. 2: Neoantigen-specific T cell activity.
From: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
a, IFNγ SFCs/million plated PBMCs at each timepoint for all peptides. N = 87 for Pre, N = 87 for Prime, N = 77 for Boost, N = 47 for Post. Statistical significance was determined by Kruskal-Wallis test corrected for multiple comparisons using Dunn’s test. Adjusted P = < 0.0001 for Pre vs. Prime, Pre vs. Boost, and Pre vs. Post. The dashed line indicates the mean value at each timepoint. b, Immunogenic peptide count for each patient at each timepoint. IFNγ SFCs/million plated PBMCs for responsive peptides for each patient in the c, adjuvant or d, metastatic cohort at each evaluable timepoint. Biospecimens were not available for analysis of GU011, GU001, GU006, and GU012 at the Post timepoint, and GU010 at the Boost timepoint. Metastatic setting n = 6 patients, adjuvant setting n = 3 patients.
